BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 20, 2018
View Archived Issues
TGF-beta inhibition restores regeneration in acute liver injury
Read More
Discovery of a druggable target for traumatic brain injury
Read More
Sumitomo Dainippon Pharma divulges dopamine D1/D2 and/or 5-HT2A receptor antagonists
Read More
Biogen patents nuclear factor erythroid 2-related factor 2 activators
Read More
Novel animal model of glaucoma created using tree shrews
Read More
New lysine-specific histone demethylase 1A inhibitors identified at Medshine Discovery
Read More
Elevated FGF23, a causative factor in the development of renal anemia and iron deficiency
Read More
Lilly discovers N-Acetyl-beta-D-glucosaminidase inhibitors
Read More
FDA approves Opdivo for metastatic SCLC that has progressed after platinum-based chemotherapy
Read More
GlaxoSmithKline describes discovery of DNMT1 inhibitors at fall ACS National Meeting
Read More
FDA places partial clinical hold on Study OX1222 of OXi-4503
Read More
Target of rapamycin complex 1 inhibition improves immune function in elderly subjects
Read More
Immunocore initiates phase I study of IMCnyeso under GSK collaboration
Read More
Tumors in brain lead to T cells in bone
Read More
Vaccinations initiated in first-in-human trial of novel attenuated Zika vaccine
Read More
Let there be no light damage
Read More
FDA approves Eylea injection sBLA in wet AMD
Read More
European clearance for phase II study of SENS-401 for sudden sensorineuronal hearing loss
Read More
Celleron enrolls first patient in phase Ib/II study of CXD-101 with nivolumab for colorectal cancer
Read More